GlaxoSmithKline Plc – Product Pipeline Review

Global Markets Direct’s, ‘GlaxoSmithKline Plc – Product Pipeline Review – 2016’, provides an overview of the GlaxoSmithKline Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GlaxoSmithKline Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of GlaxoSmithKline Plc

The report provides overview of GlaxoSmithKline Plc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses GlaxoSmithKline Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features GlaxoSmithKline Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate GlaxoSmithKline Plc’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for GlaxoSmithKline Plc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding GlaxoSmithKline Plc’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 8

GlaxoSmithKline Plc Snapshot 9

GlaxoSmithKline Plc Overview 9

Key Information 9

Key Facts 9

GlaxoSmithKline Plc - Research and Development Overview 10

Key Therapeutic Areas 10

GlaxoSmithKline Plc - Pipeline Review 22

Pipeline Products by Stage of Development 22

Pipeline Products - Monotherapy 23

Pipeline Products - Combination Treatment Modalities 24

Pipeline Products - Partnered Products 25

Pipeline Products - Out-Licensed Products 28

GlaxoSmithKline Plc - Pipeline Products Glance 30

GlaxoSmithKline Plc - Late Stage Pipeline Products 30

GlaxoSmithKline Plc - Clinical Stage Pipeline Products 33

GlaxoSmithKline Plc - Early Stage Pipeline Products 39

GlaxoSmithKline Plc - Unknown Stage Pipeline Products 43

GlaxoSmithKline Plc - Drug Profiles 44

gepirone hydrochloride ER 44

GSK-257049 46

GSK-2696273 50

mepolizumab 51

melanoma lysate vaccine 54

(fluticasone furoate + umeclidinium bromide + vilanterol trifenatate) 56

(fluticasone furoate + vilanterol trifenatate) 58

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine 60

albiglutide 61

ambrisentan 64

AS15 + recMAGE-A3 66

belimumab 68

bupropion hydrochloride ER 72

Ebola [Zaire] vaccine 73

fluticasone furoate 76

GSK-1437173A 79

inotersen sodium 81

KD-295 82

losmapimod 83

meningococcal [serotype B] vaccine 85

retosiban 87

tafenoquine succinate 88

vilanterol trifenatate 90

zanamivir 92

(batefenterol succinate + fluticasone furoate) 94

(fluticasone furoate + levocabastine hydrochloride) 95

alitretinoin 96

batefenterol 98

CAD-106 100

camicinal 102

dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide 104

danirixin 105

daprodustat 107

fluticasone furoate + umeclidinium bromide 109

gepotidacin mesylate 110

group B Streptococcus (trivalent) vaccine 112

GSK-2189242A 114

GSK-2231392A 115

GSK-2245035 116

GSK-2256098 118

GSK-2269557 120

GSK-2302032A 121

GSK-2315698 + GSK-2398852 122

GSK-2330672 123

GSK-2339345 124

GSK-239512 125

GSK-2586881 126

GSK-2696274 127

GSK-2696275 128

GSK-2789869A 129

GSK-2830930A 130

GSK-2838504A 131

GSK-2862277 132

GSK-3003891A 133

GSK-3196165 134

GSK-3277511A 136

GSK-692342 137

GSK-933776 139

GVXNSD-133 140

hepatitis C vaccine 1 141

malaria vaccine 142

mapatumumab 144

maribavir 146

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine 148

otelixizumab 149

respiratory syncytial virus vaccine 151

rilapladib 152

Streptococcal pneumonia vaccine 3 153

umeclidinium bromide 154

GSK-2302025A 156

GSK-2636771 157

GSK-525762 158

HIV [strains C1086 + TV1] (bivalent) vaccine 159

pazopanib hydrochloride + pembrolizumab 160

TDEN-PIV 161

(amlodipine besylate + rosuvastatin calcium) 162

(candesartan cilexetil + hydrochlorothiazide) 163

(diphtheria + pertussis (acellular) + tetanus) vaccine 164

1790GAHB 165

EcoXyn-4V 166

epelsiban besylate 167

FP-1039 169

GSK-1940029 171

GSK-2130579A 172

GSK-2241658A 173

GSK-2256294 174

GSK-2330811 175

GSK-2618960 176

GSK-2646264 177

GSK-2654909A 178

GSK-2654911A 179

GSK-2789868A 180

GSK-2798745 181

GSK-2800528 182

GSK-2816126 183

GSK-2831781 184

GSK-2849330 185

GSK-2857916 186

GSK-2878175 187

GSK-2879552 188

GSK-2881078 189

GSK-2981278 190

GSK-2981710 191

GSK-2982772 192

GSK-3008348 193

GSK-3117391 194

GSK-3174998 195

GSK-3206640A 196

GSK-3206641A 197

GSK-3389245A 198

hepatitis C vaccine 2 199

HIV vaccine 1 200

HIV vaccine 5 201

IMP-731 202

influenza [strain A/H5N1] vaccine 203

influenza vaccine 2 205

montelukast sodium 206

omipalisib 207

oxytocin 209

RSV-001 210

Staphylococcus aureus vaccine 211

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 212

BLyS-gel 213

Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis 214

Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa 215

GSK-030 216

GSK-1795091 217

GSK-2041706 218

GSK-214096 219

GSK-2225745 220

GSK-2394002 221

GSK-2656157 222

GSK-2795039 223

GSK-2820151 224

GSK-3039294 225

GSK-3277509A 226

GSK-3277510A 227

GSK-3326595 228

GSK-3359609 229

GSK-6288B 230

GSK-8853 231

GSKJ-4 232

GW-610742 233

HIV vaccine 2 234

influenza vaccine 235

marburg vaccine 236

meningococcal vaccine 2 237

Monoclonal Antibody Conjugate for Oncology 238

raxibacumab 239

Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis 240

Small Molecule 1 for Malaria 241

Small Molecule 1 to Inhibit Histone Methyltransferases for Cancer 242

Small Molecule 2 for Malaria 244

Small Molecule 2 for Tuberculosis 245

Small Molecule 2 to Inhibit Histone Methyltransferases for Cancer 246

Small Molecule 3 to Inhibit Histone Methyltransferases for Cancer 247

Small Molecule for Hypertension and Insulin Resistance 248

Small Molecule to Activate AMPK for Type 2 Diabetes 249

Small Molecule to Agonize S1P1 for Multiple Sclerosis 250

Small Molecules to Inhibit InhA for Tuberculosis 251

Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis 252

staphylococci aureus vaccine 253

Streptococcal pneumonia vaccine 254

TC-2153 255

tuberculosis vaccine 256

Vaccine for Alzheimer's Disease 257

Vaccine for Cancer 258

bacterial vaccine 259

bacterial vaccine 2 260

Drug for Chronic Liver Disease 261

Drugs to Antagonize T-Cell Receptor for Oncology 262

Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis 263

GSK-137647A 264

GSK-343 265

GSK-5959 266

GSKJ-1 267

Proteins for Musculoskeletal Disorders 268

Pseudomonas aeruginosa vaccine 269

Small Molecule for Tuberculosis 270

Small Molecule to Antagonize FFA4 for Undisclosed Indication 271

Small Molecule to Inhibit Histone Deacetylases for Oncology 272

Small Molecules for HIV-1 Infection 273

Small Molecules for Tuberculosis 274

Small Molecules for Undisclosed Indication 275

Small Molecules to Antagonize Folate Receptor for Tuberculosis 276

Small Molecules to Inhibit ATPase family AAA Domain-Containing Protein 2 for Oncology 277

Small Molecules to Inhibit Falcipain for Malaria 278

Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis 279

Small Molecules to Inhibit RNA Polymerase for Hepatitis C 280

(paratyphoid + typhoid) vaccine 281

GlaxoSmithKline Plc - Pipeline Analysis 282

GlaxoSmithKline Plc - Pipeline Products by Target 282

GlaxoSmithKline Plc - Pipeline Products by Route of Administration 295

GlaxoSmithKline Plc - Pipeline Products by Molecule Type 296

GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action 298

GlaxoSmithKline Plc - Recent Pipeline Updates 306

GlaxoSmithKline Plc - Dormant Projects 354

GlaxoSmithKline Plc - Discontinued Pipeline Products 363

Discontinued Pipeline Product Profiles 364

GlaxoSmithKline Plc - Company Statement 376

GlaxoSmithKline Plc - Locations And Subsidiaries 379

Head Office 379

Other Locations & Subsidiaries 379

GlaxoSmithKline Plc - Key Manufacturing Facilities 390

Appendix 391

Methodology 391

Coverage 391

Secondary Research 391

Primary Research 391

Expert Panel Validation 391

Contact Us 391

Disclaimer 392

List of Tables

List of Tables

GlaxoSmithKline Plc, Key Information 23

GlaxoSmithKline Plc, Key Facts 23

GlaxoSmithKline Plc – Pipeline by Indication, 2016 25

GlaxoSmithKline Plc – Pipeline by Stage of Development, 2016 36

GlaxoSmithKline Plc – Monotherapy Products in Pipeline, 2016 37

GlaxoSmithKline Plc – Combination Treatment Modalities in Pipeline, 2016 38

GlaxoSmithKline Plc – Partnered Products in Pipeline, 2016 39

GlaxoSmithKline Plc – Partnered Products/ Combination Treatment Modalities, 2016 40

GlaxoSmithKline Plc – Out-Licensed Products in Pipeline, 2016 42

GlaxoSmithKline Plc – Out-Licensed Products/ Combination Treatment Modalities, 2016 43

GlaxoSmithKline Plc – Pre-Registration, 2016 44

GlaxoSmithKline Plc – Filing rejected/Withdrawn, 2016 45

GlaxoSmithKline Plc – Phase III, 2016 46

GlaxoSmithKline Plc – Phase II, 2016 47

GlaxoSmithKline Plc – Phase I, 2016 50

GlaxoSmithKline Plc – IND/CTA Filed, 2016 53

GlaxoSmithKline Plc – Preclinical, 2016 54

GlaxoSmithKline Plc – Discovery, 2016 56

GlaxoSmithKline Plc – Unknown, 2016 57

GlaxoSmithKline Plc – Pipeline by Target, 2016 296

GlaxoSmithKline Plc – Pipeline by Route of Administration, 2016 309

GlaxoSmithKline Plc – Pipeline by Molecule Type, 2016 310

GlaxoSmithKline Plc – Pipeline Products by Mechanism of Action, 2016 312

GlaxoSmithKline Plc – Recent Pipeline Updates, 2016 320

GlaxoSmithKline Plc – Dormant Developmental Projects,2016 368

GlaxoSmithKline Plc – Discontinued Pipeline Products, 2016 377

GlaxoSmithKline Plc, Other Locations 393

GlaxoSmithKline Plc, Subsidiaries 393

GlaxoSmithKline Plc, Key Manufacturing Facilities 404

List of Figures

List of Figures

GlaxoSmithKline Plc – Pipeline by Top 10 Indication, 2016 25

GlaxoSmithKline Plc – Pipeline by Stage of Development, 2016 36

GlaxoSmithKline Plc – Monotherapy Products in Pipeline, 2016 37

GlaxoSmithKline Plc – Combination Treatment Modalities in Pipeline, 2016 38

GlaxoSmithKline Plc – Partnered Products in Pipeline, 2016 39

GlaxoSmithKline Plc – Out-Licensed Products in Pipeline, 2016 42

GlaxoSmithKline Plc – Pipeline by Top 10 Target, 2016 296

GlaxoSmithKline Plc – Pipeline by Route of Administration, 2016 309

GlaxoSmithKline Plc – Pipeline by Top 10 Molecule Type, 2016 310

GlaxoSmithKline Plc – Pipeline Products by Top 10 Mechanism of Action, 2016 312

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared